Roche appreciates 5.8% on promising oral anti-obesity data
NEWS. Roche finished Wednesday 5.8% up, corresponding to more than USD 16 billion in market cap, after disclosing Phase 1 data from CT-996 in obese patients, showing 7.3% weight loss (6.1% placebo-adjusted) after four weeks of treatment. Importantly, there were no treatment discontinuations, and according to the company the compound’s side effect profile is in-line with other similar molecules.
BACKGROUND. Roche entered the obesity field at the end of 2023 by acquiring Carmot Therapeutics for USD 2.7 billion with three clinical drug candidates. One of them, CT-996 is an oral small molecule targeting GLP-1, the same peptide as Novo Nordisk’s semaglutide (brand name: Wegovy, Ozempic).
COMPETITION. Although only limited data was disclosed this time, CT-996 compared favorably to peers. As an oral drug it is thought to be more convenient than injectables and as a small molecule it is easier and cheaper to manufacture than (oral) peptides, which are more complex chemical constructs built from amino acids.
More specifically, CT-996 apparently led to a numerically larger and more rapid weight loss than Viking Therapeutics’ GLP-1/GIP agonist oral peptide (5.3% weight loss in 4 weeks, 3.3% placebo-adjusted). However, Viking’s drug has a clean safety profile, while Roche did not disclose any further details on the side effects of CT-996. Roche’s drug also compares favorably to Eli Lilly’s orfoglipron and Structure Therapeutics’ GSBR-1290, that showed a 6-8% weight loss in 12 weeks. Additionally, competition is expected to intensify among oral small molecules aiming to treat obesity, as other large companies including AstraZeneca, Pfizer and Gilead are also working on similar drugs, not to mention several smaller biotech companies like Terns Pharmaceuticals, that also plan to establish themselves in the field of obesity.
UNCERTAINTIES. While comparing drugs across different clinical trials can be useful, this exercise comes several caveats. We do not know much about dose escalation in Roche’s trial - that is how frequently and to what extent did the company increase the dose during the trial – which varies trial by trial and can substantially affect the results. Additionally, no details on the side effect profile were disclosed, but Roche will present it at a medical conference, which will further clarify the picture.
CONCLUSION. To sum up, this announcement came at a favorable time for Roche. After multiple clinical setbacks in the last couple of years these favorable early results are a step towards restoring investor confidence in the company’s drug development capabilities.
Latest news
Arctic Asset Management - Apellis to be acquired by Biogen for 140% premium
On March 31, Arctic Aurora LifeScience portfolio company Apellis Pharmaceuticals announced that the company had agreed to be acquired by Biogen for an upfront cash consideration of USD 5.6 billion, representing a 140% premium on the latest closing price.
Arctic Asset Management - Arctic Midt i Måneden - Global uro, energisjokk og markedsmuligheter
Geopolitisk uro, stigende energipriser og økt markedsvolatilitet preger finansmarkedene i mars. Hva betyr dette for renter, aksjer og investorers posisjonering fremover? I denne episoden av Arctic Midt i Måneden diskuterer Albert Collett sammen med Cathrine Foyn, Tone Varmann og Alexander Larstedt Lager hvordan krig og usikkerhet påvirker markedene – og hvor mulighetene kan ligge i en urolig tid.
Arctic Asset Management - Unlocking Alpha in Biotech Through Active Selection
Yesterday, two companies in the Arctic Aurora LifeScience portfolio reported positive clinical data, which was rewarded by the market. Clinical execution and identifying companies with differentiated drug candidates yields excess returns, as demonstrated by Xenon's share price, which appreciated by close to 50% on positive data, and Dianthus, which appreciated by 21%.
Arctic Asset Management - An AI sector winner
Artificial intelligence (AI) is often portrayed as a disruptive force. In the pharmaceutical and biotechnology industries, however, it should primarily be understood as a structural value driver, enhancing productivity, improving capital efficiency and strengthening long-term competitive positioning. By compressing timelines in the discovery process and improving efficiency at the clinical and commercial stages, AI-based tools can reduce costs and meaningfully improve industry economics.
Arctic Asset Management - Markedskommentar februar 2026
I februar 2026 ble markedene påvirket av skiftende forventninger til amerikanske rentekutt, ettersom inflasjons- og arbeidsmarkedsdata var noe motstridende. Investorene fortsatte å spekulere i hvor lenge Federal Reserve ville holde politikken uendret. Store teknologi- og AI-aksjer svingte kraftig da resultater og utsikter fra ledende chip- og plattformselskaper flyttet indeksene markant. Traden bort fra programvare-aksjer fortsatte. Handelspolitikken ble også en gjentakende risikofaktor: USAs høyesterett kjente sentrale tolltiltak ulovlige, etterfulgt av nye tollgrep som økte usikkerheten for globale selskaper og verdikjeder. Mot slutten av måneden kom finanssektoren under press da bankaksjer falt på økt fokus på private-kreditt-eksponeringer og likviditetsvilkår i privatkredittprodukter rettet mot private investorer. Geopolitikk dreide seg mye om USA–Iran-spenninger og forstyrrelser på oljeprisen.
Arctic Asset Management - Arctic Midt i Måneden - Midt i rapporteringssesongen
Vi er halvveis i rapporteringssesongen, og i denne episoden av Arctic Midt i Måneden tar vi temperaturen på norske og nordiske selskaper. Hvordan har resultatene kommet inn relativt til forventningene? Hvilke sektorer leverer – og hvor straffer markedet hardest? Vi diskuterer store bevegelser på enkeltrapporter, effekten av valuta og råvarepriser, og økende marginpress i enkelte bransjer. Alexander Lager Larstedt og Herman Østensen er gjester i studio hos Albert Collett.